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Abstract
Neuroaxonal degeneration in the central nervous system contributes substantially to the long term disability in multiple
sclerosis (MS) patients. However, in vivo determination and monitoring of neurodegeneration remain difficult. As the widely
used MRI-based approaches, including the brain parenchymal fraction (BPF) have some limitations, complementary in vivo
measures for neurodegeneration are necessary. Optical coherence tomography (OCT) is a potent tool for the detection of
MS-related retinal neurodegeneration. However, crucial aspects including the association between OCT- and MRI-based
atrophy measures or the impact of MS-related parameters on OCT parameters are still unclear. In this large prospective
cross-sectional study on 104 relapsing remitting multiple sclerosis (RRMS) patients we evaluated the associations of retinal
nerve fiber layer thickness (RNFLT) and total macular volume (TMV) with BPF and addressed the impact of disease-
determining parameters on RNFLT, TMV or BPF. BPF, normalized for subject head size, was estimated with SIENAX. Relations
were analyzed primarily by Generalized Estimating Equation (GEE) models considering within-patient inter-eye relations. We
found that both RNFLT (p = 0.019, GEE) and TMV (p= 0.004, GEE) associate with BPF. RNFLT was furthermore linked to the
disease duration (p,0.001, GEE) but neither to disease severity nor patients’ age. Contrarily, BPF was rather associated with
severity (p,0.001, GEE) than disease duration and was confounded by age (p,0.001, GEE). TMV was not associated with
any of these parameters. Thus, we conclude that in RRMS patients with relatively short disease duration and rather mild
disability RNFLT and TMV reflect brain atrophy and are thus promising parameters to evaluate neurodegeneration in MS.
Furthermore, our data suggest that RNFLT and BPF reflect different aspects of MS. Whereas BPF best reflects disease
severity, RNFLT might be the better parameter for monitoring axonal damage longitudinally. Longitudinal studies are
necessary for validation of data and to further clarify the relevance of TMV.
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Introduction
Increasing evidence documents that neuronal and axonal
damage within the central nervous system (CNS) contributes
substantially to the development of permanent disability in
multiple sclerosis (MS) [1,2,3]. However, in vivo quantification
and longitudinal monitoring of neurodegenerative processes
remain a challenging task. Whole brain atrophy expressed by
brain parenchymal fraction (BPF) is a frequently used MRI-based
surrogate parameter for neurodegeneration within the CNS
[4,5,6] and an inverse relation of BPF and disability progression
has been consistently demonstrated [7,8]. However, all MRI-
based measures of brain atrophy have some important disadvan-
tages. Besides limited availability, time consumption and costs,
crucial confounders such as hydration status, inflammation,
demyelination and age have to be accounted for [5]. Thus, a
need for reliable, inexpensive and easily assessable complementary
surrogate markers for neuroaxonal degeneration still remains.
During the past two decades, optical coherence tomography
(OCT) has emerged into a fascinating tool for the non invasive and
reproducible in vivo studying of retinal neuroaxonal damage [9].
In MS patients, OCT has been consistently shown to detect
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thinning of the peripapillary retinal nerve fiber layer (RNFL)
which is most probably due to a diffuse damage of retinal axons
and at least in part independent of a previous optic neuritis (ON)
[10,11,12]. Moreover, the determination of total macular volume
(TMV) has been suggested as a marker for neuronal loss in MS
patients [13]. Therefore, OCT might be a valuable tool for
quantification and monitoring of both axonal and neuronal
damage in MS [14,15]. However, data on association between
retinal nerve fiber layer thickness (RNFLT) and MS-determining
parameters such as disease severity and disease duration are still
inconsistent [15]. Whereas some studies found an association
between RNFLT and disease duration [11,16] both parameters
were not related in other studies [17,18]. Furthermore, data
regarding the relation between OCT parameters and MRI
measures for neurodegeneration are not yet consistent and a
consensus on the most relevant parameter has yet to be reached
[5,15]. To date, the association between OCT parameters and
BPF has been addressed in only two studies. Gordon-Lipkin et al.
reported an association between RNFLT and BPF but not
between TMV and BPF in a small cohort of 40 MS patients [19].
In another small study, Siger et al. found a correlation between
RNFLT and BPF only in the subgroup without a history of ON
[20]. Thus, the relation between OCT-based measures and BPF as
an established MRI-based measure for neurodegeneration is not
yet clear.
The aims of our prospective cross-sectional study were (i) to
investigate the association between retinal neuroaxonal damage,
measured by RNFLT and TMV, and cerebral neurodegeneration,
measured by BPF, in a homogenous and sufficiently large cohort
of patients with relapsing remitting (RR)MS and (ii) to evaluate the
influence of important aspects such as age, disease duration,
disease severity and ON history on RNFLT, TMV and BPF,
respectively.
Methods
Ethics Statement
The study was approved by the local ethics committee of
Charite´ Universita¨tsmedizin Berlin, Germany, and all participants
gave informed written consent according to the 1964 Declaration
of Helsinki.
Patients
RRMS patients fulfilling the current panel criteria [21] were
prospectively recruited from baseline visit of an ongoing clinical
trial. All patients met the following criteria: age between 18 and 60
years, definite RRMS [21], expanded disability status scale (EDSS)
between 0 and 6.5 [22], stable immunomodulatory treatment with
glatiramer acetate for at least six months (this was an inclusion
criterion of the ongoing clinical trial, patients were recruited from),
no acute relapse (including optic neuritis) and no systemic steroid
treatment within 30 days prior to enrolment. Medical history,
particularly with respect to visual symptoms was taken from all
study participants. All participants underwent a complete
ophthalmologic examination including visual acuity testing,
spheric and cylindric refractive error testing and non-contact
tonometry. Patients with ophthalmologic disorders or medical
conditions with impact on OCT parameters (e.g. diabetes,
glaucoma) were not included.
Optical Coherence Tomography
All OCT examinations were carried out on a Stratus 3000
OCT (OCT3, Carl Zeiss Meditec, Dublin, USA). RNFLT was
measured using the ‘‘fast RNFL 3.4’’ protocol (software version
4.0). Three 3.4 mm diameter circular scans were acquired over
1.92 seconds. The OCT A-scan data were digitally exported in a
blinded fashion and average RNFLT was calculated. As no
specific real time volume scan protocol is available we used the
‘‘Fast Macular Thickness Map’’ protocol for determination of
TMV which interpolates the area between the real time line scans
to construct a circular model of the fovea and macula. Six radial
line scans with 128 A-scans per line and a scan area of 6-mm
diameter circle were acquired over 1.92 seconds. The maximum
of 786.432 data points for fast protocols was obtained. For
controlled manual export of the TMV data in mm3 we used the
analysis protocol ‘‘Retinal Thickness/Volume Tabular’’. A good
quality image was defined as an image with generalized signal
distribution, a reflectance signal from RNFL or retinal pigment
epithelium strong enough to identify either layer, no missing parts
caused by eye movements and a signal strength of $8 of 10 [23].
The segmentation line that defines the upper border of the retina
was required to be on the internal limiting membrane and the
lower border was required to be on the lower border of the RNFL
(for RNFLT) or between the inner and outer photoreceptor layer
of the RNFL (for TMV). Images not meeting these criteria were
excluded.
Magnetic Resonance Imaging
All MRI measurements were performed on a 1.5 Tesla scanner
(Avanto, Siemens Medical Systems, Erlangen, Germany). A three-
dimensional T1-weighted sequence (MPRAGE) was acquired
from all participants according to the following protocol: TR
1.900 ms, TE 3.09 ms, TI 1,100 ms, flip angle 15u, resolution
1 mm3). Brain tissue volume, normalized for subject head size, was
estimated with SIENAX [24,25], part of FSL [26]. SIENAX starts
by extracting brain and skull images from the single whole-head
input data [27]. The brain image is then affine-registered to
MNI152 space (using the skull image to determine the registration
scaling) [28,29]. This is primarily in order to obtain the volumetric
scaling factor, to be used as normalization for head size. Next,
tissue-type segmentation with partial volume estimation is carried
out in order to calculate total volume of brain tissue [30].
Statistical Analysis
The study was a prospective observational study with a primary
endpoint defined by a regression approach with BPF as target and
RNFLT and age as independent variables, allowing for the history
of ON. The necessary sample size was calculated using
assumptions from the study of Gordon-Lipkin [19]. For this
calculation the reported, less pronounced R2 values from the
whole MS group were used, since the RRMS subgroup’s sample
size was small and therefore of limited validity. Since no sample
size calculation is available for that approach in Generalized
Estimating Equations (GEE’s) so far, the sample size calculation
was based on linear multiple regression using the random model
that supposes both target and predictor variables as random and
should thus deliver a feasible estimation of the sample size required
for GEE. A squared multiple correlation R2 of 0.21 for RNFLT
plus age on BPF (Gordon-Lipkin et al., 2007) would be detected
with 95% power (alpha = 0.05, two-sided, k = 3 predictors) for
n = 86 patients using the random model with an exact distribution.
Considering a drop-out rate of 20% the final required sample size
was estimated to n= 103 patients. Sample size was calculated
using G*Power 3.1.2 (University of Duesseldorf, Germany) [31].
Normal distribution of outcome parameters BPF, RNFLT and
TMV (the latter two considering an influence of history of ON)
was tested using Shapiro-Wilk’s test. For BPF, RNFLT and TMV
the assumption of normality was not rejected.
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The evaluation of the primary endpoint was accomplished by a
GEE analysis with BPF as target variable and RNFLT and age as
independent variables, taking into account the history of ON.
Data of both eyes were included as repeated measures in order to
account for inter-eye correlations. The working correlation matrix
was defined as exchangeable (compound symmetry), i.e. the two
eye-measurements were supposed equally correlated and inde-
pendent from the sequence.
To address the diagnostic comparability of RNFLT or TMV
with BPF in a second step, GEE analyses were performed with
average RNFLT or TMV as independent variables and BPF as
dependent variable while allowing for the history of ON, including
again the data of both eyes as repeated measures and with an
exchangeable corresponding working correlation matrix.
The influence of age, disease duration and disease severity (as
expressed by EDSS) on BPF, RNFLT or TMV was analyzed in a
third step: GEE analyses were performed with age, disease duration
and EDSS (while allowing for the history of ON) as independent
variables and with either BPF, RNFLT or TMV as dependent
variable, using the same GEE-model specifications as before.
Since GEE in PASW 18 does not provide an output for
standardized effect sizes or regression coefficients, we actualized
this issue in the following way: age, disease duration, EDSS,
RNFLT, TMV and BPF were transformed to standardized values
and each GEE was performed with these z-values instead of the
original values, thus achieving a better comparability with other
data and understanding the effect sizes and associations.
To be able to compare our data to results reported by Gordon-
Lipkin [19] the thinner RNFLT and TMV from each patient’s
eyes were selected (‘‘minimum RNFLT’’ and ‘‘minimum TMV’’)
and used in partial correlations between BPF, minimum RNFLT
and minimum TMV controlling for age. Since partial correlations
do not account for inter-eye correlations, results from these tests
should be interpreted carefully and used only in the context of
comparability to the mentioned paper.
Significance in all tests was achieved with p,0.05. Beside the
primary endpoint, all statistical evaluations should be understood
as constituting exploratory data analysis, such that no adjustments
for multiple testing have been made.
Statistical analysis was performed using PASW 18 (SPSS/IBM,
Chicago, IL, USA).
Results
Cohort demographics
Our cohort included 104 patients (208 eyes) with RRMS. All
patients underwent clinical evaluation, OCT examination and
brain MRI. All patients with a complete data set were included in
the subsequent analysis. 62 (60%) patients never had ON on either
eye, whereas 29 patients (28%) had a history of unilateral and 13
patients (12%) of bilateral ON. Mean BPF, normalized for subject
head size was 0.852 (SD 0.033), mean RNFLT was 95.2 mm (SD
14.2 mm) and average TMV was 6.769 mm3 (SD 0.489 mm3).
Disease duration in this study was defined as time from
establishment of MS diagnosis to enrolment in the trial. Patients’
demographics and statistics are summarized in Table 1.
Association of OCT parameters with brain atrophy
The primary endpoint of our study was defined as the
association between BPF and RNFLT, using BPF as target and
RNFLT and age as independent variables and taking into account
the history of ON, which corresponds to the study by Gordon-
Lipkin [19]. In our study, the association was evaluated by GEE
analysis accounting for within-patient inter-eye dependencies. In
our cohort, BPF was predicted by patients’ age and RNFLT,
however the standardized coefficient for the association between
RNFLT and BPF was extremely low (table 2).
Next, we analyzed the associations between RNFLT or TMV
and BPF by a GEE model, which only factors the history of ON
and thus reflects better the diagnostic situation. GEE with BPF as
target and RNFLT as independent variable and accounting for the
history of ON showed a stronger though still weak association for
RNFLT (table 3 and figure 1a). Interestingly, TMV was also
associated with BPF when using the same model with TMV as
independent variable (table 3 and figure 1b).
With respect to the comparability of our data to results reported
by Gordon-Lipkin [19], we additionally performed partial
correlation analyses controlling for age and using minimum
RNFLT or minimum TMV and BPF as variables. In line with the
Table 1. Description of study cohort with demographic and
disease parameters.
RRMS-Patients n 104
Eyes n 208
Gender Male 35 (34%)
Female 69 (66%)
Age Mean (SD) 39.7 (8.8)
Range 20–59
Disease Duration [Months] Mean (SD) 68.2 (58.6)
Range 3–269
EDSS Median 2.0
Range 0.0–6.0
History of ON NON/NON 62 (60%)
NON/ON 29 (28%)
ON/ON 13 (12%)
BPF Mean (SD) 0.852 (0.032)
Range 0.77–0.922
Average RNFLT [mm] Mean (SD) 95.2 (14.2)
Range 46–133
TMV [mm3] Mean (SD) 6.769 (0.489)
Range 5.455–7.674
RRMS= relapsing remitting Multiple sclerosis; (N)ON= (non) optic neuritis;
SD = standard deviation, BPF = brain parenchymal fraction, RNFLT = retinal nerve
fiber layer thickness, TMV= total macular volume.
doi:10.1371/journal.pone.0018132.t001
Table 2. Generalized Estimating Equations for the association
of RNFLT with BPF as primary endpoint.
Beta
stand.
Beta
CI95%
Low
CI95%
High p
BPF ON 0.617
age 20.002 20.457 20.611 20.303 ,0.001
RNFLT ,0.0001 ,0.0001 ,0.0001 ,0.001 0.021
Results from GEEs with RNFLT and age as independent variables and controlling
for history of optic neuritis and BPF as dependent variable. The standardized
Beta was calculated as described in the methods section. RNFLT = retinal nerve
fiber layer thickness, ON= history of optic neuritis, CI = confidence interval.
doi:10.1371/journal.pone.0018132.t002
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GEE analyses, we found a significant but moderate correlation
between RNFLT and BPF and between TMV and BPF (table 3).
Influence of age, disease duration and severity
Having demonstrated that on the one hand both RNFLT and
TMV associate with brain atrophy and on the other hand, in the
same cohort age is strongly predictive for BPF, we asked whether
the three parameters RNFLT, TMV and BPF are linked to
distinct aspects of the disease such as age, disease duration and
disease severity as determined by EDSS. Therefore, we performed
GEE modeling with BPF, RNFLT or TMV as dependent
variables and age, disease duration and EDSS as independent
variables and correcting for history of ON. Data are presented in
table 4. In summary, the analyses confirmed that BPF is
substantially determined by both the patients’ age (p,0.001) and
EDSS (p,0.001). Notably, in our cohort BPF was not linked to
disease duration. For RNFLT our data confirmed the impact of a
previous ON as the history of ON was associated with a lower
RNFLT (p,0.001). Importantly, the only other parameter that
showed a significant impact on RNFLT was disease duration
(p,0.001). Neither age nor EDSS were linked to RNFLT. For
TMV the only determining parameter was ON history (p,0.001).
TMV was neither linked to the duration or severity of the disease
nor to the patients’ age.
Discussion
Investigating the associations between OCT parameters and BPF
as an established MRI measure for neurodegeneration in a cross-
sectional prospective study on 104 RRMS patients we here report
an association between global brain atrophy and both thinning of
the RNFL and reduction of macular volume. In line with previous
studies, reduction of both average RNFLT and TMV was linked to
the history of ON. Importantly, apart from the impact of ON,
RNFL thinning correlated closely with disease duration whereas
BPF was determined by age and disease severity. TMV associated
neither with disease duration, disease severity nor age.
The strengths of our study are the large sample size, the prospective
design, the homogeneity of our study cohort including exclusively
RRMS patients on a stable immunomodulatory treatment, the
evaluation of the influence of disease duration, disease severity and age
on RNFLT, TMV or BPF in the same population, and a statistical
approach taking within-patient inter-eye relations into account. On
the other hand, with respect to our cohort characteristics which reflect
patients with relatively short disease duration and mild to moderate
disability, our results should not be uncritically transferred to MS
populations with different characteristics.
Although OCT receives increasing attention as future tool for the
detection and monitoring of neurodegenerative processes in MS the
evaluation of the actual value of this technique remains difficult.
Table 3. Generalized Estimating Equations for the association
of RNFLT or TMV with BPF.
GEE
controlled for ON
Partial Correlation
controlled for age
Beta stand. Beta p R p
RNFLT ,0.0001 0.0001 0.019 0.269 0.006
TMV ,0.0001 0.0002 0.004 0.369 ,0.001
Results from GEEs with RNFLT or TMV as independent values and controlling for
history of optic neuritis and BPF as dependent variable are given in columns 2–
4. The standardized Beta was calculated as described in the methods section.
Additionally, partial correlation coefficients controlling for age are displayed in
the last two columns to allow comparability to previous results [19]. P-values
are given in parentheses. RNFLT = retinal nerve fiber layer thickness, TMV= total
macular volume, ON=history of optic neuritis, GEE =Generalized Estimating
Equations.
doi:10.1371/journal.pone.0018132.t003
Figure 1. Association between BPF and OCT parameters in patients with RRMS. Patients (individual eyes) are labeled according to the
history of optic neuritis (ON). Lines are derived from linear regression analyses with R2 given in parentheses. Statistical significance level was
calculated by Generalized Estimating Equation models controlling for the history of ON. A) Retinal nerve fiber layer thickness (RNFLT) vs. BPF (0.073,
p = 0.019). B) Total macular volume (TMV) vs. BPF (0.113, p = 0.001).
doi:10.1371/journal.pone.0018132.g001
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This is mainly, because on the one hand, the interrelations between
neurodegenerative processes in the retina and the brain are still
under investigation and on the other hand, the impact of disease-
related aspects such as duration and severity and disease-unrelated
parameters such as age on OCT parameters is not yet clear [5,15].
The only published two previous studies addressing the correlation
of OCT parameters with BPF included only a limited number of
patients (between 18 and 40) or inhomogeneous disease courses and
did not account for within-patient inter-eye relations [19,20]. In the
present cohort we used a statistical model which allows adjusting for
within-patient inter-eye relations and corrected for the history of
ON, which we consider an appropriate approach in a population
with different ON status. Our primary endpoint reflects the
statistical model used by Gordon-Lipkin and was primarily defined
for the estimation of the sample size. However, for the evaluation of
associations between BPF and RNFLT or TMV we favor our
second GEE model which does not account for disease duration,
disease severity or age and thus represents a rather diagnostic than
pathophysiological point of view. Since GEE does not provide
standardized output for correlation coefficients we additionally
calculated a ‘‘standardized Beta’’ in order to provide a better
conception of the effect sizes. Using this model, the association
between BPF and RNFLT was significant but weak (table 3,
figure 1a). Interestingly, when applying the same statistical
approach as Gordon-Lipkin et al., which however does not account
for inter-eye dependencies, we also found an association between
minimumRNFLT and BPF but with a moderate partial correlation
coefficient (table 3), which is in line with Gordon-Lipkin [19]. In
contrast to Siger et al. who found an association of RNFLT and BPF
only in a cohort subgroup without ON [20], in our study the
correlation was evident in the total cohort.
With respect to TMV our data (according to both GEE and
partial correlation analyses; table 3) contrast Gordon-Lipkin et al.,
who did not find a correlation between TMV and BPF and
suggested that ‘‘in a cohort of patients with MS with a mean
duration of disease of approximately 10 years, TMV may be less
informative than in a cohort with a longer history of MS’’ [19]. Our
data rather indicate, that TMV in fact reflects global brain atrophy
already after a mean disease duration of approximately five years
and even in patients with a predominantly mild clinical disability
(table 1) and suggest that damage to retinal ganglion cells occurs
already in earlier phases of the disease. That in turn would be in line
with grey matter damage detected early in the disease course by
MRI or histopathology [32,33,34]. The differences in our data
compared to previous data [19,20] may be at least partially
explained by the larger sample size in our study and the different
cohort characteristics. The different effect sizes estimated by GEE
and partial correlations might indicate, that at least in a cohort with
a comparably short disease duration and mild disability, partial
correlation analysis with minimum RNFLT/TMV not factoring
inter-eye dependencies, might overestimate the strength of
associations. It remains to be seen whether in a currently running
longitudinal study factoring the changes within the parameters over
time the standardized beta will conform to the partial r.
Numerous studies have addressed the relations between RNFLT,
TMV or BPF with disease duration, disease severity, ON history
and age in individual cohorts with different characteristics
(summarized and meta-analyzed in two recent major review articles
[5,15]). However, data are still inconsistent. For example, a
correlation between disease duration and thinning of RNFL has
been reported in some studies [11,16,20,35] whereas others did not
find a correlation [17,18]. Consequently, the ability of each marker
RNFLT, TMV and BPF, respectively, to capture distinct aspects of
the disease remains unclear. Evaluating the impact of disease
duration, severity and age on each of the MRI and OCT
parameters within the same cohort by GEE and correcting for the
ON history, we here demonstrate that BPF might be a good
parameter for the evaluation of the disease severity as, in line with
previous reports [8], it associated best with the EDSS. On the other
hand, our observations that in the same experimental setting
RNFLT but not BPF were linked to the disease duration and that
furthermore BPF but not RNFLT was substantially confounded by
the patients’ age, which is in line with previous reports [19], suggest
that RNFLT is the better parameter for duration-related issues such
as longitudinal monitoring in clinical trials. The relevance of TMV
remains elusive, as TMV was not associated with any of the
parameters. TMV captures not only the retinal nerve fiber layer,
but also deeper layers of the retina, which in particular in
combination with the use of time-domain OCT might render
TMV a less specific parameter for neuroaxonal degeneration.
Furthermore, as the sample size calculation was based on RNFLT
this study was not powered to primarily investigate the role of TMV.
Not surprisingly, our data moreover confirmed the impact of ON on
RNFLT and TMV demonstrated in previous studies [12,15].
In summary, our cross-sectional data on the association between
both RNFLT and TMV with BPF point to a significant but weak
association which was at least in our cohort independent of a
previous ON. RNFLT and BPF but not TMV are linked to certain
aspects of MS. Whereas BPF reflects in the first place the severity
of the disease, RNFLT might be the better parameter for
monitoring axonal damage longitudinally. Thus we conclude that
in addition to BPF at least RNFLT is a promising complementary
parameter to evaluate early neurodegenerative processes in
RRMS patients. The eligibility of TMV as surrogate marker
requires further evaluation. Longitudinal studies and studies on
patients with a longer disease duration and higher disability are
necessary to corroborate the relevance of these parameters and to
clarify the remaining questions. We therefore suggest that both
Table 4. Correlation between age, disease duration and
severity with BPF, RNFLT and TMV.
Beta
stand.
Beta
CI95%
Low
CI95%
High p
BPF age 20.001 20.334 20.499 20.168 ,0.001
duration 0.098
EDSS 20.005 20.223 20.390 20.057 ,0.001
ON 0.067
RNFLT age 0.585
duration 20.073 20.299 20.471 20.128 ,0.001
EDSS 0.201
ON 29.597 20.675 20.906 20.444 ,0.001
TMV age 0.230
duration 0.088
EDSS 0.240
ON 20.300 20.614 20.818 20.410 ,0.001
Beta coefficients, standardized Beta coefficients, confidence interval for
standardized beta coefficients and p values are provided as calculated by
Generalized Estimating Equations accounting for inter-eye dependencies with
age, duration, EDSS and history of optic neuritis as independent variables and
RNFLT, TMV or BPF as dependent variables. For better clarity, coefficients are
only given for factors that reached statistical significance. Standardized Beta
was calculated as described in the Methods section. BPF =brain parenchymal
fraction, RNFLT = retinal nerve fiber layer thickness, TMV= total macular volume,
ON=history of optic neuritis, CI = confidence interval.
doi:10.1371/journal.pone.0018132.t004
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RNFLT and TMV should be included as standard secondary
endpoints in clinical trials addressing neurodegeneration in MS.
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